Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...
Both are sold by Danish drug giant Novo Nordisk. The generic liraglutide is sold by Hikma Pharmaceuticals USA, and a spokesman told CNN by email that the company expects to make the drug available ...